An anti-inflammatory drug candidate, known as 3,6’-dithiopomalidomide (DP), designed by researchers at the National Institute on Aging (NIA), protected lab mice against cognitive decline by reducing brain inflammation. An international research team led by the NIA scientists published their findings in Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association. NIA is part of the National Institutes of Health.
The study results provide new evidence that brain inflammation — which occurs decades before Alzheimer’s symptoms are noticeable — is a key neuropathological pathway of interest in efforts to find potential treatments for Alzheimer’s.
To investigate whether brain inflammation was directly involved in cognitive loss, researchers used a mouse model specially designed to produce up to five times the normal levels of beta-amyloid plaques. These plaques are a hallmark sign of Alzheimer’s and are thought to contribute to a destructive inflammatory response in the brain. After four months of treatment with DP, the mice showed reduced brain inflammation and neuron death, and they had more neural connections in the brain areas responsible for memory and attention. DP-treated mice also showed improvement in behavioral laboratory tasks that test spatial and working memory as well as anxiety behaviors and motor function, results the researchers see as protective against cognitive impairment.
WHO
Study Lead Author:
- Nigel Greig, Ph.D., chief, Drug Design and Development Section, NIA Intramural Research Program
Broader Perspectives:
- Richard J. Hodes, M.D., director, NIA
- Luigi Ferrucci, M.D., scientific director, NIA
NIA spokespeople are available by phone or virtually for interviews.
The research was funded in part by the NIH Intramural Research Program grant ZIAAG000994 and NIA grant R56AG057028.
Reference:
Lecca D, et al. Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis. Alzheimer’s & Dementia. 2022. doi:10.1002/alz.12610.
